Skip to content

Schering-Plough SGP Investing Cash Flow

Investing Cash Flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
-$1.04B-250%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$428.9M-166%
Glaukos logo
GlaukosGKOS
$10.5M+128%
AbbVie logo
AbbVieABBV
-$574M+21.9%
Bausch + Lomb logo
Bausch + LombBLCO
-$130M-12.1%
HRO
HarrowHROW
-$18.2M-8,486%

Other financials

Income statement

See full
Operating income-$15.4M-108%
Net income-$13.8M-56.6%
EPS (diluted)-$0.69+82.6%

Balance sheet

See full
Cash & equivalents$238.9M+312%
Total debt$1.6M
Total equity$250.1M+463%
Total assets$258.4M

Cash flow

See full
Operating cash flow-$13.5M-65.2%
CapEx$676.0K+312%
Free cash flow-$14.2M-70.0%

Valuation

See full
Market cap$744.23M-23.4%
Enterprise value$506.93M

Returns & leverage

See full
Return on equity-34.3%
Debt / equity
Current ratio38×

Where this comes from

Reported directly by Schering-Plough in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Schering-Plough’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schering-Plough's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Schering-Plough's investing cash flow?
Schering-Plough (SGP) reported investing cash flow of -$1.67M in Q1 2026.
How has Schering-Plough's investing cash flow changed year-over-year?
Schering-Plough's investing cash flow decreased by 916.5% year-over-year, from -$164K to -$1.67M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.